LivaNova PLC
No SEC Form 4 filings for $LIVN in the last 30 days.
LivaNova PLC announced that Stefano Folli will join the company as President of its Cardiopulmonary business unit, effective June 1. He will succeed Franco Poletti, who is retiring on July 31, with a transition period expected over several months. Folli, who previously held leadership roles at Philips, will oversee the strategic growth of the nearly $800 million business.
Tudor Investment Corp ET AL recently acquired a new stake of 33,332 shares in LivaNova PLC (LIVN) during the third quarter, valued at approximately $1.75 million. Institutional ownership of LivaNova is high at 97.64%, with other firms like Parkman Healthcare Partners LLC also significantly increasing their holdings. LivaNova reported strong Q3 earnings, beating analyst estimates, and provided positive FY2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $74.78.
The FDA has approved LivaNova's aura6000 System, a neurostimulator for adults with moderate to severe obstructive sleep apnea (OSA) who cannot use other therapies. This device is notable as the first approved in the US without a complete concentric collapse contraindication or the need for pre-implantation drug-induced sleep endoscopy. Clinical trials demonstrated a 65% responder rate at 12 months, with significant improvements in AHI and ODI.
